About (AKES) Akeso Inc.

Company Background

Akeso Inc., symbol AKES (TRADU:AKES), is a leading biopharmaceutical company headquartered in Zhuhai, China, specializing in the discovery, development, and commercialization of innovative antibody therapeutics. Founded in 2012, Akeso focuses on addressing major unmet medical needs in oncology, immunology, and other critical disease areas. The company has developed a robust pipeline of over 30 innovative drug candidates, including both monoclonal and bispecific antibodies. Akeso operates an integrated biopharmaceutical platform that spans research, clinical development, manufacturing, and commercialization, enabling efficient and high-quality drug development from concept to market. Its mission is to improve human health and quality of life through cutting-edge biotechnological innovation.

Market Position

Akeso Inc. holds a strong and rapidly growing position in China’s biotechnology and pharmaceutical sector. The company is widely recognized for its pioneering work in bispecific antibody technology, which allows the targeting of multiple disease pathways simultaneously. Its flagship product, Cadonilimab (AK104)—a first-in-class PD-1/CTLA-4 bispecific antibody—received regulatory approval in China and marked a major milestone in domestic biotech innovation. Akeso’s expanding global partnerships and licensing deals further enhance its international presence, allowing it to compete effectively with global pharmaceutical leaders. The company’s integrated R&D capabilities and state-of-the-art manufacturing facilities position it as one of the most advanced biopharma innovators in Asia, driving progress in immuno-oncology and precision medicine.

Key Financial and Industry Highlights

Akeso demonstrates solid financial momentum supported by a diversified clinical pipeline, strategic collaborations, and growing commercial revenues. The company’s business model emphasizes sustainable innovation through continuous investment in research and development, accounting for a significant portion of annual expenditures. Its successful drug launches and expanding portfolio of late-stage clinical assets strengthen long-term revenue visibility. Akeso’s partnerships with global pharmaceutical firms have also facilitated international commercialization and accelerated its entry into new markets.

As global healthcare shifts toward targeted therapies and immuno-oncology breakthroughs, Akeso Inc. is well-positioned to capitalize on the growing demand for next-generation biologics. Its commitment to scientific excellence, patient-centric development, and sustainable innovation underscores its vision of becoming a world-class biopharmaceutical leader. With a strong foundation in antibody engineering and a proven track record of innovation, Akeso continues to drive advancements that redefine the future of biomedicine both in China and globally.